Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Wellsite
Re "looks like loose ends and tidy up ready for BH to make their move to me"
I guess it's your one great wish for Provexis, but I can't see us being taken over by ByHealth in the short to medium term. Putting in place contracts with a supplier ( us ) for Jan 2023 doesn't sound like the sort of thing that ByHealth would do just before making an offer for a company, but wtfdIk ?
BB
Wellsite
Re "looks like loose ends and tidy up ready for BH to make their move to me"
I guess it's your one great wish for Provexis, but I can't see us being taken over by ByHealth in the short to medium term. Putting in place contracts with a supplier ( us ) for Jan 2023 doesn't sound like the sort of thing that ByHealth would do just before making an offer for a company, but wtfdIk ?
BB
OK I won't keep banging on about this. I've read other people's views (thank you), I'll take them on board. I'm clearly not as enthusiastic at this news as some on here so let's hope you're right and I'm wrong. I'm in the fortunate position now where I don't need to sell here, I can hold as long as it takes (my average is 103 so I'm there or there abouts anyway) so let's see what happens. Good luck all, thanks again for contributions, talk again no doubt. K
Is it not a good thing provexis taking co3 back ,meaning from the last if dsm breaks even they will give provexis control back
The Thread you are posting on is titled?
I agree Krusty BH need to rescue us or put us out of our misery. Getting out of the DSM deal might be a precursor to M&A ,? BH would want to buy us out prior to any sales getting off the ground in China imo. Give us 2p and I'll be happy wish I'd never heard of PXS.
Could you clarify how "this will be lost" ?
Provexis will receive the revenues for all sales, apart from the sales resulting from development of the new patent. (Years away)
Who then, would we "lose" the income to?
FF is produced in batches...the manufacturer only takes orders for full batches.
PXS gets a percentage in the current AA for the FF content of their own FF+O caps. This will be lost in the new deal.
The new agreement doesnt kick in until 1 Jan 2023 so it's effect won't be seen until Y/E 2022/23 results next year but mainly in 2023/2024 half year.
Who makes FF+O caps and box them for PXS...Gixer didn't we think this was a service provided by DSM? Whoever it is they provide same service for PXS's Chinese Distributor. Do we know how well he's doing?
Servicing existing accounts with FF might not be too difficult but growing new ones will be a hill to climb with existing PXS personnel...not been very successful with own product in the UK to date...
Looking at the trading band PXS has been in and the fact they are no longer listed on the DSMV site it does look like DSM might be working a get out through a friendly third party.
Krusty
following on from gixer's comments, worth bearing in mind some in the tomato industry have been trying to get a piece of the FF action for many years, and so far failed.
https://www.tomatonews.com/en/the-tomato-foundation-health-claim-project_2_360.html
Puts us in a good bargaining imho
W$
(U R probably right about the sp though)
" (just to remind you, our sales for the year are forecast to be less than half a million quid)"
Not strictly true. Our share of the profit from sales are forecast to be less than half a million quid. Who knows what profit DSM is making from that sales volume but I would guess its more than we get.
Do we know if DSM has "buyer clout" with Indena (manufacturer of FF) or is Fruitflow the only product they manufacture for DSM?
Wow, have you guys actually worked in industry? Buying power is partly down to volume, I agree, and we've seen precious little of that so far (just to remind you, our sales for the year are forecast to be less than half a million quid). But it's also a product of buyer clout. DSM can outsource (buy) off the back of letting multi million £ contracts whereas PXS might be forced to sign volume-related contracts where low volume = high cost. Meanwhile, DSM has got that annoying little monkey off it's back and no longer has to fart about with it. I love your optimism guys, always have, but I don't see much positivity in this new arrangement whereas I do see lots of danger flags. For me, By-Health is the only reason to remain invested here now. The market agrees with you guys though, for now at least. Let's see if we're back to .80 - .90 by Friday as I suspect.
Plus, as stated, Provexis are the supplier to By Health under the terms of that agreement, therefore volumes should be substantial from the time of transfer. Win-win.
Current levels of business, and demand from the inherited clients, doesn't add more costs, as all can be outsourced. To develop further outside if the China market would require a sales force. The scale and projected costs of that will be interesting to see in future updates.
Also,
Who do you think could sell Fruitflow at a lower price. Provexis or PXS and DSM combined.
RE: "Who do you think has more buying power to negotiate price - DSM or PXS??"
Price will be down to volume and not who is buying IMO.
everhopeful, the expense element I'm more concerned about it this: "DSM will help facilitate the transfer of its wholly outsourced supply chain / production process for Fruitflow from DSM to Provexis with effect from 1 January 2023". Who do you think has more buying power to negotiate price - DSM or PXS??
Great news 20% reduction in loss:only £173 k this year
Question is what will DSM do with their shareholding now ?
Will Frederic offski ?
Will SL come on board ?
W$
The new agreement will mean more expenses , PXS now need a sales manager replacing DSMs sales expertise can't be overlooked . ( But were DSM pulling their weight ?) Why did DSM let go and give it back? We need the Chinese to come to the rescue imo. More detail needed on the missing 3 attributes too.
Great news to see PXS bring Fruitflow back in house as a raw material...however, they will now be responsible for the Receivables and maintaining/expanding sales. Many of the companies who launched products containing fruitflow fell at the first hurdle. I think Gixer might still have an idea of who is actively still out there.
Now the DSM reins are off and if Bi-Heath products are successful then IF might be persuaded to take early retirement...
Yes he has. Shame its not reflected in a much higher SP. Caught the MMS off guard. No leaky ship at PXS I will certainly be adding more to my 10 million plus shares
IF has pulled off a blinder here !!
DP64, I'm sure you're aware of the chatter on SAR about naming examples of 10-fold takeover bids, what makes you think PXS could achieve that? Let the science play out and the share re-rate to 10p naturally, then look to attract bids. It'll take longer but be much, much more worthwhile for LTH's. All IMHO of course, I know others are keen for this to be bought out.
Looks very +ve and we will be profitable very soon. All the loose ends are tied up for BH to make a good offer once we are profitable.. Probably a price tag of ~10p will be good offer as SM got out ~7p. So hold tight and wait for the big days.
Turnover still lower than most teenagers working out of their bedrooms at home. Still a long way to go here, and with the Chinese regulatory changes holding up By-Health's blue hat claim it could be a while yet before the potential is unlocked. We all know it's going to happen sooner or later though, so I guess the wait continues.